Mizuho analyst Salim Syed lowered the firm’s price target on Cytokinetics to $99 from $103 and keeps a Buy rating on the shares. Any potential acquisition premium that was still left in the stock is likely removed by now, the analyst tells investors in a research note. The firm says a possible capital raise, if there is one in 2024, could come after any potential Japan/aficamten deal.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics to Participate in March Investor Conferences
- Calix to replace Cytokinetics in S&P 600 at open on 3/18
- Cytokinetics to replace Calix in S&P 400 at open on 3/18
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
